Tyra Biosciences Appoints New Director, Adjusts Executive Pay

Ticker: TYRA · Form: 8-K · Filed: Jan 29, 2025 · CIK: 1863127

Tyra Biosciences, Inc. 8-K Filing Summary
FieldDetail
CompanyTyra Biosciences, Inc. (TYRA)
Form Type8-K
Filed DateJan 29, 2025
Risk Levellow
Pages4
Reading Time4 min
Key Dollar Amounts$0.0001
Sentimentneutral

Sentiment: neutral

Topics: board-changes, executive-compensation, governance

TL;DR

Tyra Bio adds a director and tweaks exec pay, effective Jan 28.

AI Summary

On January 28, 2025, Tyra Biosciences, Inc. announced changes to its board of directors and executive compensation. Specifically, Dr. Jeffrey W. Chen was appointed as a new director, and the company entered into new employment agreements with certain officers, including an amended and restated employment agreement with its Chief Medical Officer, Dr. Todd M. W. Johnson.

Why It Matters

Changes in board composition and executive compensation can signal shifts in company strategy or management's confidence in future performance.

Risk Assessment

Risk Level: low — The filing reports routine corporate governance changes and executive compensation adjustments, which are common and typically do not indicate significant new risks.

Key Players & Entities

  • Tyra Biosciences, Inc. (company) — Registrant
  • Dr. Jeffrey W. Chen (person) — Newly appointed director
  • Dr. Todd M. W. Johnson (person) — Chief Medical Officer
  • January 28, 2025 (date) — Effective date of reported events

FAQ

Who was appointed as a new director to Tyra Biosciences, Inc.'s board?

Dr. Jeffrey W. Chen was appointed as a new director.

What is the effective date of the events reported in this 8-K filing?

The earliest event reported is dated January 28, 2025.

Did Tyra Biosciences, Inc. make any changes to executive compensation?

Yes, the company entered into new employment agreements with certain officers, including an amended and restated employment agreement with its Chief Medical Officer.

What is the principal executive office address for Tyra Biosciences, Inc.?

The principal executive offices are located at 2656 State Street, Carlsbad, California, 92008.

What is the SIC code for Tyra Biosciences, Inc.?

The Standard Industrial Classification code for Tyra Biosciences, Inc. is 2834, Pharmaceutical Preparations.

Filing Stats: 1,053 words · 4 min read · ~4 pages · Grade level 10.5 · Accepted 2025-01-29 16:05:13

Key Financial Figures

  • $0.0001 — ich registered Common Stock, par value $0.0001 per share TYRA Nasdaq Global Select

Filing Documents

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. TYRA BIOSCIENCES, INC. Date:January 29, 2025 By: /s/ Alan Fuhrman Alan Fuhrman Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.